FDA’s second approval of an amyloid imaging agent, GE Healthcare's Vizamyl, reinforced the viability of the regulatory path for radiopharmaceutical imaging drugs that target beta amyloid even as the agency continues to question the usefulness of such scans in clinical practice.
The development of PET amyloid imaging agents “rests on the notion that the detection of β amyloid in brain scans...